Glofitamab clinical trials
Also written RO7082859 and Columvi.
How each study uses glofitamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the glofitamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Jun 2023 · COLUMVI · BLA 761309 (FDA, Drugs@FDA)
- European Union
- 7 Jul 2023 · Columvi · EMEA/H/C/005751 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
60 studies that test it; most in 2026 (20); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 7 |
| 2024 | 8 |
| 2025 | 12 |
| 2026 | 20 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 49
Hoffmann-La Roche (13) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (4) · Ruijin Hospital (3) · City of Hope Medical Center (3) · The Lymphoma Academic Research Organisation (2) · The First Affiliated Hospital with Nanjing Medical University (2) · The First Affiliated Hospital of Soochow University (2)
Often tested with
Tested in the same studies.
Obinutuzumab (8) · Lenalidomide (6) · Polatuzumab vedotin (6) · Gemcitabine (5) · Oxaliplatin (5) · Venetoclax (3) · Rituximab (3) · Mosunetuzumab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 17, 2 in phase 3
Studies that test glofitamab, phase 3 first.
- Aug 2027A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaPhase 3 · Hoffmann-La Roche
- Oct 2027An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaPhase 3 · Hoffmann-La Roche
- Dec 2026Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell LymphomaEarly Phase 1 · Canadian Cancer Trials Group
- Dec 2026Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCLPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Feb 2027Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaPhase 1/2 · City of Hope Medical Center
- Mar 2027A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaPhase 1 · Hoffmann-La Roche
- Mar 2027Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLPhase 2 · Shanghai Zhongshan Hospital
- Jun 2027Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaPhase 2 · M.D. Anderson Cancer Center
- Jul 2027Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsPhase 2 · Joshua Brody
- Jul 2027Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses glofitamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 62
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingPhase 2Hoffmann-La RocheNCT06806033Written as Glofitamab
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07003295Written as Glofitamab
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as Glofitamab
- Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaRecruitingPhase 1City of Hope Medical CenterNCT06922604Written as Glofitamab
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07917832Written as Glofitamab
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Glofitamab
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Hoffmann-La RocheNCT05533775Written as Glofitamab
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")RecruitingPhase 1National Cancer Institute (NCI)NCT07649304Written as Glofitamab
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06054776Written as Glofitamab
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06213311Written as Glofitamab
- Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasRecruitingPhase 2American University of Beirut Medical CenterNCT07387848Written as Glofitamab
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaRecruitingPhase 1/2City of Hope Medical CenterNCT05861050Written as Glofitamab
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07888621Written as Glofitamab
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as Glofitamab
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingPhase 2Shanghai Zhongshan HospitalNCT07012980Written as Glofitamab
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2University of California, San FranciscoNCT06252675Written as Glofitamab
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Glofitamab
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as Glofitamab
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07774234Written as Glofitamab
- Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT07749365Written as hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab
See all 62 studies that test glofitamab →
Given beside what is tested · 17 — glofitamab is usual care or a partner of the new treatment
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06765317Written as Glofitamab
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Glofitamab
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Glofitamab
- MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)RecruitingPhase 2Ryvu Therapeutics SANCT06534437Written as Glofitamab
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Glofitamab
- A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingPhase 1Arvinas Inc.NCT06393738Written as Glofitamab
- Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07613788Written as Glofitamab
- Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruitingPhase 2Ruijin HospitalNCT07326371Written as Glofitamab
- Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06996132Written as Glofitamab
- A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingPhase 2Ruijin HospitalNCT06656221Written as Glofitamab
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive, not recruitingPhase 1/2Hoffmann-La RocheNCT04077723Written as Glofitamab
- An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedPhase 1/2Hoffmann-La RocheNCT03533283Written as Glofitamab
- Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaActive, not recruitingPhase 1/2University of WashingtonNCT04231877Written as Glofitamab
- A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)Active, not recruitingPhase 1ADC Therapeutics S.A.NCT04970901Written as Glofitamab
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedPhase 1/2PfizerNCT05896163Written as Glofitamab
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedPhase 1Hoffmann-La RocheNCT03467373Written as Glofitamab
- A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)Active, not recruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04914741Written as Glofitamab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting5
- Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaNov 6, 2026NCT06922604
- Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell LymphomasOct 29, 2026NCT07387848
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")Oct 28, 2026NCT07649304
- Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell LymphomaOct 26, 2026NCT05861050
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaOct 22, 2026NCT07711483
Newly registered2
- Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell LymphomaNov 5, 2026NCT07917832
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaOct 22, 2026NCT07888621
Codes
What other systems call glofitamab · ClinicalTrials.gg INT001741
- MeSH (NLM) C000720108glofitamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 06P3KLK2J8GLOFITAMABConfirmed FDA, NLM, Wikidata
- Wikidata Q117846135glofitamabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148486GlofitamabOne source FDA
- DrugBank DB16371One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720108 | glofitamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 06P3KLK2J8 | GLOFITAMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q117846135 | glofitamab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148486 | Glofitamab | One source FDA |
| DrugBank | DB16371 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.